KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of “Moderate Buy” by Brokerages

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $29.1667.

KALV has been the subject of a number of recent analyst reports. Citigroup restated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Needham & Company LLC raised their price target on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. HC Wainwright upped their price objective on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, January 9th. Finally, Citizens Jmp cut their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research report on Tuesday, November 11th.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,294 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $16.51, for a total transaction of $120,423.94. Following the transaction, the chief executive officer directly owned 424,520 shares in the company, valued at approximately $7,008,825.20. This represents a 1.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Brian Piekos sold 4,471 shares of the stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $13.45, for a total transaction of $60,134.95. Following the completion of the transaction, the chief financial officer directly owned 10,529 shares of the company’s stock, valued at approximately $141,615.05. This trade represents a 29.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 31,329 shares of company stock valued at $437,371. Corporate insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently bought and sold shares of KALV. AQR Capital Management LLC acquired a new position in KalVista Pharmaceuticals during the first quarter worth $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of KalVista Pharmaceuticals by 13.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock valued at $281,000 after buying an additional 2,939 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of KalVista Pharmaceuticals by 3.7% in the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company’s stock valued at $3,923,000 after buying an additional 12,263 shares in the last quarter. Whalen Wealth Management Inc. acquired a new position in shares of KalVista Pharmaceuticals during the 2nd quarter worth $124,000. Finally, Emerald Advisers LLC boosted its position in shares of KalVista Pharmaceuticals by 15.6% in the 2nd quarter. Emerald Advisers LLC now owns 1,038,049 shares of the specialty pharmaceutical company’s stock worth $11,735,000 after buying an additional 139,859 shares in the last quarter.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV opened at $14.77 on Tuesday. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The firm has a market cap of $746.62 million, a price-to-earnings ratio of -3.74 and a beta of -0.19. The firm’s fifty day moving average price is $15.64 and its 200 day moving average price is $13.79. KalVista Pharmaceuticals has a 1-year low of $8.84 and a 1-year high of $19.00.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.04. The firm had revenue of $13.69 million during the quarter, compared to analyst estimates of $6.03 million. On average, sell-side analysts expect that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.